Format

Send to

Choose Destination
Schizophr Res. 2014 Jan;152(1):283-8. doi: 10.1016/j.schres.2013.11.014. Epub 2013 Dec 2.

A controlled family study of cannabis users with and without psychosis.

Author information

1
Harvard Medical School, 25 Shattuck St, Boston, MA 02115, United States.
2
Harvard Medical School, 25 Shattuck St, Boston, MA 02115, United States; Veterans Administration Boston Healthcare System, 940 Belmont St, Brockton, MA 02301, United States.
3
Harvard Medical School, 25 Shattuck St, Boston, MA 02115, United States; Veterans Administration Boston Healthcare System, 940 Belmont St, Brockton, MA 02301, United States. Electronic address: Lynn_DeLisi@hms.harvard.edu.

Abstract

BACKGROUND:

Cannabis is one of the most highly abused illicit drugs in the world. Several studies suggest a link between adolescent cannabis use and schizophrenia. An understanding of this link would have significant implications for legalization of cannabis and its medicinal value. The present study aims to determine whether familial morbid risk for schizophrenia is the crucial factor that underlies the association of adolescent cannabis use with the development of schizophrenia.

METHODS:

Consecutively obtained probands were recruited into four samples: sample 1: 87 non-psychotic controls with no drug use; sample 2: 84 non-psychotic controls with cannabis use; sample 3: 32 patients with a schizophrenia spectrum psychosis with no drug use; sample 4: 76 patients with schizophrenia spectrum psychosis with cannabis use. All cannabis using subjects used this drug during adolescence, and no other substance, with the exception of alcohol. Structured interviews of probands and family informants were used to obtain diagnostic information about probands and all their known relatives.

RESULTS:

There was an increased morbid risk for schizophrenia in relatives of the cannabis using and non-using patient samples compared with their respective non-psychotic control samples (p=.002, p<.001 respectively). There was no significant difference in morbid risk for schizophrenia between relatives of the patients who use or do not use cannabis (p=.43).

CONCLUSIONS:

The results of the current study suggest that having an increased familial morbid risk for schizophrenia may be the underlying basis for schizophrenia in cannabis users and not cannabis use by itself.

PMID:
24309013
PMCID:
PMC4319545
DOI:
10.1016/j.schres.2013.11.014
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center